Lyell Immunopharma, Inc. announced it raised $493 Million in an initial filing from an offering of $493 Million

Company

Location

About

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company specializing in next-generation cell therapies for cancer patients. It is publicly listed on Nasdaq under the symbol LYEL. The company aims to bring meaningful and durable clinical benefit to patients by focusing on next-generation CAR T-cell therapies and proprietary technologies designed to generate longer-lasting, functional T cells to achieve more durable outcomes for patients with solid tumors and hematologic malignancies.